IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2700
-0.0100 (-0.44%)
At close: 4:00PM EDT

2.2700 0.00 (0.00%)
After hours: 5:53PM EDT

Stock chart is not supported by your current browser
Previous Close2.2800
Open2.2700
Bid2.1600 x 2200
Ask2.4900 x 900
Day's Range2.2200 - 2.3100
52 Week Range1.7600 - 10.3900
Volume1,481,215
Avg. Volume3,738,146
Market Cap339.435M
Beta (3Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-1.2060
Earnings DateJul 25, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.67
Trade prices are not sourced from all markets
  • Will ImmunoGen Continue to Surge Higher?
    Zacks6 days ago

    Will ImmunoGen Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor ImmunoGen.

  • Penny Stocks to Buy Using Technical Analysis for July 2019
    Investopedia20 days ago

    Penny Stocks to Buy Using Technical Analysis for July 2019

    Short-term traders can profit from volatility generated by global uncertainty. These penny stock trades could be profitable this month.

  • ImmunoGen axes 75% of staff to fund new clinical trial
    American City Business Journals20 days ago

    ImmunoGen axes 75% of staff to fund new clinical trial

    After its Phase 3 trial failed, ImmunoGen has opted to continue testing its ovarian cancer drug in a subgroup of patients with high rates of a protein called folate receptor alpha.

  • Here’s What Hedge Funds Think About ImmunoGen, Inc. (IMGN)
    Insider Monkey21 days ago

    Here’s What Hedge Funds Think About ImmunoGen, Inc. (IMGN)

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]

  • Business Wire21 days ago

    ImmunoGen Announces Completion of Operational Review

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of an in-depth operational review designed to extend the Company’s cash runway and deliver on its commitment to develop next-generation ADCs to bring more good days to patients and generate increased value for shareholders. Based on the outcomes of this review, the Company will prioritize continued development of mirvetuximab and a select portfolio of three earlier-stage product candidates targeting solid tumors and hematological malignancies. The Company will end the current quarter with approximately $240 million on its balance sheet and expects this cash, together with expense reductions resulting from the operational changes announced today and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

    NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (IMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether ImmunoGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?
    Zacks2 months ago

    Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?

    ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga2 months ago

    The Week Ahead In Biotech: ASCO Presentations In The Spotlight

    After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...

  • Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
    Zacks2 months ago

    Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Benzinga2 months ago

    Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.

  • ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
    Zacks2 months ago

    ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

    FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

  • What Analysts Recommend for IMGN after Its Q1 Results
    Market Realist2 months ago

    What Analysts Recommend for IMGN after Its Q1 Results

    Why Did Immunogen Stock Crash on May 15?(Continued from Prior Part)Recent share price movementsOn May 15, Immunogen (IMGN) issued a press release announcing mature data from its FORWARD II expansion cohort, which is evaluating the combination of

  • Why Immunogen Was Down by More than 30% on May 15
    Market Realist2 months ago

    Why Immunogen Was Down by More than 30% on May 15

    Why Did Immunogen Stock Crash on May 15?Recent regulatory updateOn May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial evaluating mirvetuximab soravtansine monotherapy in high folate

  • Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today
    Motley Fool2 months ago

    Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today

    Despite a solid gain in the market, these companies struggled.

  • Why ImmunoGen Shares Are Crashing Today
    Motley Fool2 months ago

    Why ImmunoGen Shares Are Crashing Today

    Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate.

  • TheStreet.com2 months ago

    ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

    plunged more than 30% on Wednesday after the company revealed that the U.S. Food and Drug Administration has recommended further trials to "evaluate the safety and efficacy" of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy - a treatment it has been developing for patients with certain forms of ovarian cancer. In response, the FDA told ImmunoGen that because the data results produced to date have not been able to meet expectations, "... the study could not be used to support an application for accelerated approval," ImmunoGen said in a statement.

  • MarketWatch2 months ago

    ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug

    Shares of ImmunoGen, Inc. fell 32% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration recommended conducting a new Phase 3 trial of its ovarian cancer drug, mirvetuximab soravtansine. A recent trial looking at the drug as an ovarian cancer therapy did not meet its primary endpoint. ImmunoGen met with the FDA this past week to discuss the trial and a potential path forward, and the agency provided guidance on trial design and endpoints, the company said. "Our meeting with FDA enabled us to clarify a regulatory path forward for mirvetuximab and we are evaluating all avenues to bring this promising therapy to ovarian cancer patients," Immunogen Chief Executive Mark Enyedy said in a statement. The Waltham, Mass.-based biotech has been working on mirvetuximab as a potential treatment for patients with ovarian cancer who haven't responded to platinum treatment and who also test positive for high folate receptor α. Shares of the biotech have fallen 34% so far this year through Tuesday, while the S&P 500 has gained 13%.

  • Business Wire2 months ago

    ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration (FDA) has recommended that the Company conduct a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer as part of a Type C meeting held this week. ImmunoGen requested the meeting to discuss the results of the Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy. FDA acknowledged that platinum-resistant ovarian cancer is a disease with unmet need, provided guidance regarding the design and endpoints of a potential registration study, and encouraged the Company to return to discuss a proposed study design.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMT

    Q1 2019 ImmunoGen Inc Earnings Call

  • ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
    Zacks2 months ago

    ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

    ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.